Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03214172 · ClinicalTrials.gov registry record
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT03214172 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,000 participants.
The verdict
NCT03214172 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2017-07-15 |
| Est. Completion | 2017-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03214172
The ClinicalTrials.gov registry entry for NCT03214172 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT03214172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03214172 about?
NCT03214172 is a clinical study titled "Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban". To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
What is the current status of trial NCT03214172?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2017-07-15. Estimated completion is 2017-09-15.
What interventions are being tested in trial NCT03214172?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG).
Who is sponsoring clinical trial NCT03214172?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.